Enact
Pharma Appoints Dr. Richard Goodfellow as a Non-Executive Director
Monday
27th May 2002
Enact
Pharma plc, the market driven biopharmaceutical company, has appointed Dr.
Richard Goodfellow, as a non-executive Director. The Board now consists of
three Executive Directors and four non-Executive Directors.
Dr.
Goodfellow will play a key role helping to develop the commercial strategy
for the Company and in particular will lead an active alliance building
programme with other biotechnology companies and the major pharmaceutical
groups.
Dr
Goodfellow has over 20 years international experience in the
pharmaceutical industry in both Big Pharma and biotechnology companies.
During his time at Astra, he oversaw the launch of Losec and other key
products internationally. Whilst at Scotia he
negotiated a number of global deals and was involved in the company's
flotation on the London Stock Exchange.
A
regular speaker at many key industry events, a co-founder of the Cambridge
based Drug Discovery Company Paradigm Therapeutics and a Director of
Scancell, a company developing monoclonal antibodies and vaccines for the
treatment of cancer, Dr. Goodfellow brings to Enact a wealth of knowledge
and experience.
Commenting
on his appointment Dr. Goodfellow said: "Enact has an impressive
portfolio of oncology products in both early and later stage development
and the potential to become an important player in the UK Biotechnology
sector. I am looking forward to working with the Enact team to help the
Company meet its ambitious objectives."
-ends-
For
further information please contact:
Mel
Choi
WMC
Communications Ltd
Ph :
0207 591 3999
Email :
melissa.choi@wmccommunications.com
About
Enact:
Enact
Pharma is an emerging biopharmaceutical company. An OFEX listed company,
Enact Pharma has focused on the research and development of anti-cancer
therapies and other products for the treatment of neuropathological
diseases. Enact is the result of a merger in April 2000 between Enzacta
and Kymed. The Company is based in the UK, with a small research and
development facility at Porton Down near Salisbury, and offices at
Salisbury and Heyford Park. The combined investment in the merged company
to date is approximately £6.2 million.
Enact's
strengths are a committed management and scientific team, a strong product
portfolio, which has now been developed and validated to enter clinical
trials, and its ability to both identify and create commercial
opportunity. The Company is now in a position to proceed independently to
a Phase I trial of its lead product NQ02. The NQ02 clinical trial will
create the first major step increase in company value and initiate a
significant revenue flow to develop the Company's rich product portfolio.
The
Team:
Chief
Executive Officer -Dr Tony Atkinson, previously Deputy Director of the
Centre for Applied Microbiology and Research and Director of its Division
of Biotechnology, a founder of Kymed and a number of other companies.
Previously Chief Scientific Officer of Enact Pharma.
Chief
Operational Officer - Dr Judy McArdell, previously COO of Kymed and a
founder of both New Sarum Enterprises Ltd and Tetricus Ltd the incubator
company for the development of the Porton Down Science Park.
Acting
Finance Director - Mr James Cooper was previously a Director of Hambros
Bank working in the Corporate Finance Division and Co-Head of UK Corporate
Finance for BNP Paribas in London.
Director
- Dr Jon Dickens, formerly CEO of Enzacta, which merged with Kymed to form
Enact Pharma and a founder of British Biotech Ltd and later executive
director of Chiroscience.
